Shopping Cart
- Remove All
Your shopping cart is currently empty
Casein Kinase II Inhibitor IV is an inducer of epidermal keratinocyte differentiation.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $79 | In Stock | |
| 5 mg | $173 | In Stock | |
| 10 mg | $273 | In Stock | |
| 25 mg | $451 | In Stock | |
| 50 mg | $636 | In Stock | |
| 100 mg | $858 | In Stock | |
| 500 mg | $1,710 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $190 | In Stock |
| Description | Casein Kinase II Inhibitor IV is an inducer of epidermal keratinocyte differentiation. |
| In vitro | Treatment with Casein Kinase II Inhibitor IV on human epidermal keratinocytes (NHEKs) enhances early differentiation markers, keratins 1 and 10, at 48 hours, while increasing levels of IVL and TGM at 72 hours, sustained through 96 hours. This inhibitor also prompts the expression of loricrin, a terminal differentiation marker, at subsequent time points. Correspondingly, mRNA expression analysis confirms upregulation of early differentiation marker genes, specifically keratin 1 and keratin 10 by 5.4-fold at 12 and 24 hours. Late-differentiation marker genes, including IVL (1.8-fold), TGM 1 (4.8-fold), loricrin (3.3-fold), and filaggrin (5.6-fold), exhibit increased expression at 36 and 48 hours in NHEKs treated with Casein Kinase II Inhibitor IV. |
| Molecular Weight | 429.47 |
| Formula | C24H23N5O3 |
| Cas No. | 863598-09-8 |
| Smiles | COc1cc(Nc2ncc3ccn(-c4cccc(CCC#N)c4)c3n2)cc(OC)c1OC |
| Relative Density. | 1.25 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 70 mg/mL (162.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.66 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.